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Abstract Respiratory syncytial virus (RSV) infection
involves complex virus-host interplay. In this study, we
analyzed gene expression in RSV-infected BEAS-2B cells
to discover novel signaling pathways and biomarkers. We
hybridized RNAs from RSV- or vehicle-treated BEAS-2B
to Affymetrix HU133 plus 2.0 microarrays (n = 4). At 4
and 24 h post-infection, 277 and 900 genes (RSV/control
ratio C2.0 or B0.5), and 1 and 12 pathways respectively
were significantly altered. Twenty-three and 92 genes at 4
and 24 h respectively matched respiratory disease bio-
markers with ARG2 flagged at 24 h and SCNN1G,
EPB41L4B, CSF1, PTEN, TUBB1 and ESR2 at both time
points. Hierachical clustering showed a cluster containing
ARG2 and IL8. In human bronchial epithelial cells, RSV
upregulated arginase II protein. Knockdown of ARG2
increased RSV-induced IL-8, LDH and histone release.
With microarray, we identified novel proximal airway
epithelial cell genes that may be tested in the sputum
samples as biomarkers of RSV infection.
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Introduction
Respiratory syncytial virus (RSV), a negative-stranded
RNA virus, is a common viral pathogen capable of causing
respiratory tract infection and acute lung injury. In chil-
dren, RSV bronchiolitis is estimated to cause 91,000 hos-
pital admissions per year in the United States (Openshaw
2005). RSV is the pathogen in up to 50% of children
hospitalized with bronchiolitis and 25% of children with
pneumonia (Hall and McCarthy 1995). In adults, RSV may
cause severe pneumonia with high mortality, especially in
patients with underlying cardiopulmonary illnesses, the
elderly and the immunocompromised (Falsey and Walsh
2000; La Montagne 1997). RSV infection also predisposes
to the development of acute lung injury (Hammer et al.
1997; Hertz et al. 1989; Zaroukian et al. 1988).
The bronchial epithelial cell is the primary target of
RSV. When RSV enters the respiratory tract, the surface
proteins G (attachment) and F (fusion) of the virus interact
with a heparan sulfate located on the bronchial epithelial
cell surface (Feldman et al. 2000) (Levine et al. 1987).
Once inside the cells, RSV replicates and assembles using
the actin cytoskeleton (Ulloa et al. 1998) (Burke et al.
1998; Burke et al. 2000) (Werling et al. 1999) (Parton et al.
1994). Although the mechanisms by which RSV causes
epithelial infection and injury are not entirely clear, there is
increasing evidence that much of the pathology caused by
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RSV is due to the immune response to the infection
(Openshaw 1995, 2005). Replication and proliferation of
RSV inside the cells induce Th1/Th2 immune responses
(Peebles and Graham 2005) (Welliver et al. 2002). The
infected epithelial cells and immune cells release proin-
flammatory cytokines and chemokines that may result in
acute lung injury (Krishnan et al. 2004). Inappropriate
activation of the Th2 cellular immune response and depo-
sition of antigen–antibody immune complexes may trigger
complement activation and modulate the severity of RSV-
induced cellular injury (Graham 1995; Openshaw 1995,
2005; Polack et al. 2002).
Our knowledge of the pathogenesis of RSV-induced
lung infection is incomplete in part due to the complex
virus-host cell interplay following the infection. Many
previous studies have focused on specific aspects of the
host response against RSV. Several microarray studies also
have been reported (Kong et al. 2003; Martinez et al. 2007;
Zhang et al. 2001). These studies provided a global view of
gene expression during the complex virus-host cell inter-
actions, but they were performed in transformed human
alveolar epithelial cells using smaller arrays (A549 cells).
It is unclear whether or not these events in distal lung cells
could be extrapolated to the epithelial cells of proximal
airways, which are early targets of RSV infection. In
addition, clinical diagnosis of RSV infection still relies on
the demonstration of the virus in the biological specimens.
It is unclear how these gene biomarkers obtained in distal
lung cells may help clinical diagnosis since these cells are
less available. Thus in this study, we examined gene
expression profile in human bronchial epithelial cells using
microarray technology. The main goals were to explore
signaling pathways and genes that may be used as bio-




For microarray experiments, human bronchial epithelial
cell line (BEAS-2B, subclone S6) was obtained from the
laboratory of Dr. Curtis C. Harris and maintained in serum-
free growth medium (KGM, Clonetics, San Diego, CA) in
T75 tissue culture flasks. The cells were used in experi-
ments in their 62nd to 73rd passage. Cells were plated at
100 mm-diameter tissue culture plates (Costar, Cambridge,
MA) in KGM and incubated at 37C and 5% CO2 for 72 h
before they were used for microarray experiments.
Primary human bronchial epithelial cells (HBEC) were
also used for all non-microarray experiments (including
PCR confirmation and siRNA).These primary cells were
obtained from normal volunteers through bronchoscopic
bronchial brushings (Ghio et al. 2000; Huang et al. 2003).
Subjects were informed of the procedures and potential
risks and each signed an informed consent. The protocol
was approved by the University of North Carolina School
of Medicine Committee on Protection of the Rights
of Human Subjects and US Environmental Protection
Agency. All brushings were processed by a single experi-
enced technician following the established standard of
procedures in our laboratory. The cells (passage 2 or 3)
were maintained in bronchial epithelial growth medium
(BEGM) (Clonetics, San Diego, CA), supplemented with
bovine pituitary extract, insulin 5 lg/ml, hydrocortisone
0.5 lg/ml, gentamicin 50 lg/ml, retinoic acid 0.1 ng/ml,
transferrin 10 lg/ml, triiodothyrodine 6.5 ng/ml, epineph-
rine 0.5 lg/ml, human epidermal growth factor 0.5 ng/ml.
Preparation of RSV
RSV (Long strain/lot 15D) was obtained from American
Type Culture Collection (Bethesda, MD) and was propa-
gated in mycoplasma-free HEp2 cells (ATCC 23-CCL,
Bethesda, MD) as previously described (Becker et al.
1997). HEp2 supernatants containing infectious RSV were
collected and the virus was precipitated using 10% poly-
ethylene glycol (Sigma, St. Louis, MO). The precipitate
was dissolved in NTE (50 mM Tris-HCl, 150 mM NaCl,
1 mM EDTA), pH 7.4, and overlaid on a discontinuous 60,
45, and 30% sucrose gradient made up in NTE. After
centrifugation for 90 min at 85,0009g in a Sorvall TH-641
rotor, the virus was collected from the 45–60% interface.
This preparation contained *1 9 107 plaque-forming
units (PFU)/ml of RSV when tested for syncytia formation
on HEp2 cells. The virus was snap frozen in liquid nitrogen
and stored in small aliquots at -70C until use.
RSV infection
For microarray experiments, confluent monolayer cultures
of BEAS-2B were infected with RSV at a multiplicity of
infection (MOI) of 1.0 PFU/cell. Virus was added to the
cells for 2 h and then removed by a gentle wash with
culture medium, followed by addition of 1 ml/well fresh
KGM for 4 or 24 h (Soukup and Becker 2003). The control
cells were incubated with vehicle.
Purification and hybridization of RNA
Total cellular RNA was extracted from the cells with Trizol
reagent (GIBCO BRL Life Technologies, Gaithersburg,
MD) and further purified with phenol/chloroform. The
RNA integrity was assessed with an Agilent 2100 bioan-
alyzer (Agilent Technologies, Inc, Pao Alto, CA). The
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260 nm/280 nm ratios for all RNAs were[1.9. The RNAs
were hybridized to Hu133 plus 2.0 gene chips (Affymetrix,
Inc, Santa Clara CA). The chip contained probes for 38,500
human genes. The hybridization was performed by the
Expression Analysis, Inc. (Durham, NC) according to the
‘‘Affymetrix Technical Manual’’. Briefly, total RNA
(10 lg) was converted into cDNA using Reverse Trans-
criptase (Invitrogen Corp, Carlsbad, CA) and a modified
oligo(dT)24 primer that contains T7 promoter sequences
(GenSet Corp, San Diego, CA). After first strand synthesis,
residual RNA was degraded by the addition of RNaseH and
a double-stranded cDNA molecule was generated using
DNA polymerase I and DNA ligase. The cDNA was then
purified and concentrated using a phenol: chloroform
extraction followed by ethanol precipitation. The cDNA
products were incubated with T7 RNA Polymerase and
biotinylated ribonucleotide using an In Vitro Transcription
kit (Enzo Diagnostics, Inc, New York, NY). One-half of
the cRNA products were purified using an RNeasy column
(Qiagen Inc, Valencia, CA) and quantified with a spec-
trophotometer. The cRNA target (20 lg) was incubated at
94C for 35 min in fragmentation buffer (Tris, magnesium
acetate, potassium acetate). The fragmented cRNA was
diluted in hybridization buffer (2-morpholinoethane-
sulfonic acid, NaCl, EDTA, Tween 20, herring sperm
DNA, acetylated bovine serum albumin) containing biotin-
labeled OligoB2 and Eukaryotic Hybridization Controls
(Affymetrix). The hybridization cocktail was denatured at
99C for 5 min, incubated at 45C for 5 min and then
injected into a GeneChip cartridge. The GeneChip array
was incubated at 42C for at least 16 h in a rotating oven at
60 rpm. GeneChips were washed with a series of non-
stringent (25C) and stringent (50C) solutions containing
variable amounts of 2-morpholinoethanesulfonic acid,
Tween20 and SSPE (3 M NaCl, 0.2 M, NaH2PO4, 0.02 M
EDTA). The microarrays were then stained with Strepta-
vidin Phycoerythrin and the fluorescent signal was ampli-
fied using a biotinylated antibody solution. Fluorescent
images were detected in a GeneChip Scanner 3000 and
expression data was extracted using the default settings in
the MicroArray Suite 5.0 software (Affymetrix). All
GeneChips were scaled to a median intensity setting of
500. A total of 9 microarrays were performed, including
control and RSV (1.0 MOI) at 4 and 24 h (n = 3 biological
replicates). The vehicle-treated cells were harvested at 24 h
and used as the control for all RSV experiments.
Microarray data analysis
The microarray data were deposited in the Gene Expres-
sion Omnibus website (http://www.ncbi.nlm.nih.gov/geo/)
(accession number GSE3397). Gene expression values
were background-corrected and normalized globally using
the default setting of the Affymetrix Microarray Suite
version 5.0 and log2-transformed according to the ‘‘Af-
fymetrix Statistical Algorithm Reference Guide’’. The log2
signal ratios of RSV over control for all probe sets were
compared to zero using the one class t-test with a p of
\0.05 using the Multi experiment Viewer (MeV version
3.0, The Institute of Genomic Research, Rockville, MD).
Genes that showed statistically significant expression over
control and a cut-off fold change of [2.0 or \0.5 were
retained. If more than one probe set for the same gene were
flagged, their ratios were averaged. Only data from three
microarray experiments were analyzed because one of the
control data sets was found to be very different from the
other three controls during the clustering analysis.
Pathway and biomarkers analysis
The differentially expressed genes at 4 and 24 h post-
infection were categorized based on the KEGG_Pathway
using the Database for Annotation, Visualization and
Integrated Discovery (DAVID, version 2006) (http://niaid.
abcc.ncifcrf.gov/). Pathways with p B 0.1 were considered
significant. We also used Venn diagram and Ingenuity
Pathway Analysis (http://www.ingenuity.com) (Ingenuity
System, Inc, Redwood City, CA) to identify potential
biomarkers for respiratory diseases.
Quantitative polymerase chain reaction (Q-PCR)
Q-PCR was performed for selected genes. cDNAs were
synthesized from 0.4 lg of total RNA in 100 ll of buffer
containing 5 lM random hexaoligonucleotide primers
(Pharmacia, Piscataway, NJ), 10 U/ll Moloney murine
leukemia virus reverse transcriptase (GIBCO BRL Life
Technologies), 1 U/ll RNase inhibitor (RNasin, Pro-
mega, Madison, WI), 0.5 mM dNTP (Pharmacia), 50 mM
KCl, 3 mM MgCl2 and 10 mM Tris-HCl (pH 9.3) for 1 h
at 39C. Reverse transcriptase was heat-inactivated at 94C
for 4 min.
Q-PCR of specimen and standard cDNA was completed
using TaqMan pre-developed assay reagents. Quantitative
fluorogenic amplification of cDNA was performed using
the ABI Prism 7500 Sequence Detection System, primers
and probes of interest and TaqMan Universal PCR Master
Mix (Applied Biosystems). The relative abundance of
mRNA levels was determined from standard curves gen-
erated from a serially diluted standard pool of cDNA pre-
pared from control HPAEC cultures. The relative
abundance of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, Unigene accession #544577) mRNA was used to
normalize levels of the mRNAs of interest. For Q-PCR
verification, RNA from six additional experiments was
collected. RNA samples for microarray and Q-PCR were
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collected from different experiments and do not represent
the same sample.
Cytokine/chemokine measurements
IL-8 and CSF2 (GMCSF) in the medium were measured
using ELISA kits purchased from R&D Systems (Minne-
apolis, MN) according to the manufacturer’s directions.
The detection limit for the kits was 10 pg/ml.
Western blot analysis
After the exposure, the cells were washed once with ice
cold phosphate-buffered saline (PBS) and then lysed with
radioimmunoprecipitation (RIPA) buffer (1% Nonidet P-
40, 0.5% sodium deoxycholate, and 0.1% SDS in PBS, pH
7.4) containing 0.1 mM vandal sulfate and protease
inhibitors (0.5 mg/ml aprotinin, 0.5 mg/ml E-64, 0.5 mg/
ml pepstatin, 0.5 mg/ml bestatin, 10 mg/ml chymostatin,
and 0.1 ng/ml leupeptin). The cell lysates were then cen-
trifuged at 3,000g for 10 min at 4C. Protein concentration
of supernatant was measured with Bio-Rad protein assay
reagent. Cellular proteins were separated by 10% SDS–
PAGE and transferred to a polyvinylidene difluoride
membrane. The blot was blocked with 5% milk in PBS
with 0.05% Tween-20 for 1 h at room temperature, washed
briefly, and then probed with a rabbit antibody against
human arginase II (Catalog# sc-20151, Santa Cruz Bio-
technology, Santa Cruz, CA) overnight at 4C. This was
followed by incubation with HRP-conjugated secondary
antibodies. Bands were detected by using ECL and films.
Transfection of HBEC with arginase II siRNA
Cells were grown to *60–70% confluency in 6-well
plates. They were then transfected with Gene Silencer
transfecting agent plus (Gene Therapy System, Inc, San
Diego, CA) with arginase II siRNA (100 nM) (Catalog#
sc-29729, Santa Cruz Biotechnology, Santa Cruz, CA) in
serum-free EGM-2 medium for 3 h according to the
manufacturer’s recommendation. Control cells were incu-
bated with Gene Silencer negative control #1 siRNA
(Ambion, Inc, TX). Fresh EGM-2 medium with 2% fetal
bovine serum was then added and cells were cultured for an
additional 24 h. Cells were then treated with RSV or
vehicle as described above. Cell lysates were collected at
24 and 48 h post-infection and arginase II protein expres-
sion was measured by western blotting.
Statistical analysis
All non-microarray data are expressed as mean ± standard
errors (SE). Data from multiple groups were analyzed by
one way analysis of variance (ANOVA) followed by the
Tukey’s subtest for between-group comparisons. The sta-
tistical analysis was performed using StatView (version
5.0.1, SAS, Inc, Cary NC). A p value of \0.05 was con-
sidered statistically significant.
Results
Gene expression profile induced by RSV
Using the statistical algorithm, we found 2,630 probes
differentially expressed at 4 h post-infection. After elimi-
nating duplicate and non-annotatable probes, there were
277 genes with a RSV/control ratio C2.0 or B0.5. Of these
genes, 106 were upregulated and 171 were downregulated.
KEGG pathway analysis using these genes showed the
neuroactive ligand-receptor interaction as the only signifi-
cant pathway. There were 11 genes in this pathway
(p = 0.012) (Table 1). The expression of these genes at
24 h after RSV infection is also shown in Table 1. Com-
pared to the 4-h time point, the expression of many of these
genes remained altered, although the fold changes were
smaller.
At 24 h post-infection, we identified 6,818 probes dif-
ferentially expressed. After eliminating duplicate and non-
annotatable probes, there were 912 genes with a RSV/
control expression ratio C2.0 or B0.5. KEGG pathway
analysis of the 912 genes identified 12 pathways (Table 2).
These pathways include P52 signaling pathway, apoptosis,
the JAK-STAT signaling pathway and the cytokine-cyto-
kine receptor interaction known to be related to RSV
infection. Genes in these pathways are shown in Tables 3,
4, 5 and 6 respectively. Several genes in the cytokine-
cytokine receptor interaction pathway, e.g., CSF1, CSF2
and IL2, already had increased expression at 4 h after
infection. Other pathways mapped with at least ten genes
included ubiquitin mediated proteolysis (16 genes), prostate
cancer (11 genes), small cell lung cancer (11 genes), cell
cycle (13 genes), and hematopoietic cell lineage (10 genes).
We confirmed upregulation of 7 genes with Q-PCR in
independent experiments (Fig. 1). In addition, we con-
firmed that RSV increased the release of IL-8 and CSF2 in
a dose-dependent manner (Fig. 2). In microarray, IL-8 and
CSF2 gene expression was increased by more than 3 and
20-fold respectively.
Pathways and biomarkers analysis
Using Venn diagram, we found 129 genes were upregu-
lated and 192 genes were downregulated at both 4 and 24 h
post-infection (Fig. 3). The top 10 up- and down-regulated
genes are listed in Table 7. We also mapped the significant
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genes at 4 and 24 h post-infection to Biomarker Filter
(Ingenuity Pathways Analysis) to identify potential bio-
markers for respiratory diseases. We identified 23 and 92
genes at 4 and 24 h respectively, that were the biomarkers
linked to respiratory diseases. Six genes were differentially
expressed at both time points (Fig. 4). Four genes
(SCNN1G, EPB41L4B, CSF1, PTEN) were upregulated
and one gene (TUBB1) was down-regulated at both time
points. ESR2 was upregulated at 4 h, but downregulated at
24 h post-infection.
Role of arginase II in RSV-induced epithelial injury
In examining the 24-h genes (92 genes) that were bio-
markers for respiratory diseases, we noted ARG1 and
ARG2 were among the upregulated genes (2.2 and 2.1-fold
Table 1 Genes in the neuroactive ligand-receptor interaction pathway that were differentially expressed at 4 h (4 H) after RSV infection. Fold
changes at 24 h (24 H) are also shown
UniGene Symbol Fold Gene name
4 H 24 H
Hs.388226 HCRTR1 5.37 2.26 Hypocretin (orexin) receptor 1
Hs.258580 P2RX2 5.14 3.59 Purinergic receptor p2x, ligand-gated ion channel, 2
Hs.530653 GRID1 2.92 1.47 Glutamate receptor, ionotropic, delta 1
Hs.200262 TACR1 2.41 1.15 Tachykinin receptor 1
Hs.405348 AGTR2 2.35 1.12 Angiotensin II receptor, type 2
Hs.302026 NPFFR1 -2.00 -2.09 Neuropeptide FF receptor 1
Hs.251412 GIPR -2.27 -1.30 Gastric inhibitory polypeptide receptor
Hs.147361 GRM5 -2.27 -1.52 Glutamate receptor, metabotropic 5
Hs.7195 GABRG2 -2.50 -1.86 Gamma-aminobutyric acid (gaba) A receptor, gamma 2
Hs.348500 VIPR1 -2.56 1.08 Vasoactive intestinal peptide receptor 1
Hs.2131 AVPR1A -3.23 -1.39 Arginine vasopressin receptor 1a
Table 2 Pathways associated with RSV infection at 24 h
Pathways Gene count p value
p53 signaling pathway 12 0.002
Circadian rhythm 5 0.0059
Ubiquitin mediated proteolysis 16 0.011
Jak-STAT signaling pathway 17 0.019
Cytokine–cytokine receptor interaction 24 0.032
Prostate cancer 11 0.034
Small cell lung cancer 11 0.034
Cell cycle 13 0.039
Terpenoid biosynthesis 3 0.046
Apoptosis 10 0.063
Hematopoietic cell lineage 10 0.067
Methionine metabolism 4 0.090
Table 3 Genes in P53 signaling pathway that were differentially expressed at 24 h (24 H) after RSV infection. Fold changes at 4 h (4 H) are
also shown
UniGene Symbol Fold Gene name
4 H 24 H
Hs.446564 DDB2 1.39 7.50 Damage-specific DNA binding protein 2, 48 kDa
Hs.567303 MDM2 -1.07 4.74 MDM2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)
Hs.469543 SESN2 1.32 3.13 Sestrin 2
Hs.467020 BBC3 1.44 3.02 BCL2 binding component 3
Hs.110571 GADD45B 1.18 2.76 Growth arrest and DNA-damage-inducible, beta
Hs.96 PMAIP1 -1.04 2.61 Phorbol-12-myristate-13-acetate-induced protein 1
Hs.500466 PTEN 1.06 2.11 Phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
Hs.370771 CDKN1A 1.04 2.07 Cyclin-dependent kinase inhibitor 1A (p21, CIP1)
Hs.295923 SIAH1 -1.55 2.02 Seven in absentia homolog 1 (Drosophila)
Hs.558304 CASP8 -1.58 -2.63 Caspase 8, apoptosis-related cysteine peptidase
Hs.24529 CHEK1 -1.05 -2.86 CHK1 checkpoint homolog (s. Pombe)
Hs.567387 CCNE2 -1.39 -4.00 Cyclin E2
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respectively). Since arginase II is the major arginase iso-
form in the bronchial epithelial cells (Que et al. 1998), we
further investigated the role of arginase II in RSV-induced
bronchial epithelial infection. We first performed the
hierarchical clustering analysis using the 912 differentially
expressed genes at 24 h post-infection (Fig. 5a). We
located the smallest cluster that contained ARG2. There
were 11 genes in this cluster, including IL8, a major RSV-
induced chemokine gene (Fig. 5b).
In separate experiments, we confirm that RSV upregu-
lated arginase II protein expression by fourfold (Fig. 6).
We then incubated HBEC with arginase II siRNA for 24 h
before treating the cells with RSV. Arginase II siRNA
knocked down constitutive and RSV-induced arginase II
protein expression by more than 75% (Fig. 7a). Knock-
down of arginase II expression increased RSV-induced
release of IL-8 (Fig. 7b), LDH (Fig. 7c) and histone
(Fig. 7d), consistent with the putative role of arginase II as
a repair enzyme (Curran et al. 2006; Satriano 2003; Witte
and Barbul 2003).
Discussion
At 4 and 24 h after RSV infection of human bronchial
epithelial cells, approximately 5 and 12.5% of the probe sets
Table 4 Genes in the apoptosis pathway that were differentially expressed at 24 h (24 H) after RSV infection. Fold changes at 4 h (4 H) are also
shown
UniGene Symbol Fold Gene name
4 H 24 H
Hs.127799 BIRC3 1.53 5.88 Baculoviral IAP repeat-containing 3
Hs.81328 NFKBIA 1.41 4.58 Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
Hs.278901 PIK3R5 -0.26 3.98 Phosphoinositide-3-kinase, regulatory subunit 5, p101
Hs.356076 XIAP 1.03 2.32 X-linked inhibitor of apoptosis
Hs.449207 IRAK2 1.14 2.22 Interleukin-1 receptor-associated kinase 2
Hs.516966 BCL2L1 1.11 2.05 BCL2-like 1
Hs.557403 IL1R1 -1.17 -2.27 Interleukin 1 receptor, type I
Hs.213467 TNFRSF10D -1.26 -2.27 Tumor necrosis factor receptor superfamily, member 10D, decoy with truncated death domain
Hs.86131 FADD -1.21 -2.33 Fas (TNFRSF6)-associated via death domain
Hs.558304 CASP8 -1.58 -2.63 Caspase 8, apoptosis-related cysteine peptidase
Table 5 Genes in JAK-STAT signaling pathway that were differentially expressed at 24 h (24 H) after RSV infection. Fold changes at 4 h (4 H)
are also shown
UniGene Symbol Fold Gene name
4 H 24 H
Hs.1349 CSF2 4.04 21.38 Colony stimulating factor 2 (granulocyte–macrophage)
Hs.411311 IL24 1.21 4.52 Interleukin 24
Hs.278901 PIK3R5 1.56 3.98 Phosphoinositide-3-kinase, regulatory subunit 5, p101
Hs.120658 OSMR 1.45 3.76 Oncostatin M receptor
Hs.389874 TSLP 1.44 3.52 Thymic stromal lymphopoietin
Hs.272373 IL20 1.09 3.26 Interleukin 20
Hs.430589 CBLB 1.20 2.73 Cas-Br-M (murine) ecotropic retroviral transforming sequence b
Hs.18676 SPRY2 1.23 2.58 Sprouty homolog 2 (Drosophila)
Hs.2303 EPO 1.40 2.49 Erythropoietin
Hs.81170 PIM1 1.33 2.47 PIM-1 oncogene
Hs.89679 IL2 4.05 2.44 Interleukin 2
Hs.23581 LEPR 1.17 2.24 Leptin receptor
Hs.520414 IFNGR1 1.21 2.19 Interferon gamma receptor 1
Hs.516966 BCL2L1 1.11 2.05 BCL2-like 1
Hs.531081 SOCS4 -1.30 -2.27 Suppressor of cytokine signaling 4
Hs.181315 IFNAR1 1.01 -3.45 Interferon (alpha, beta and omega) receptor 1
Hs.567294 IL12RB1 -2.61 -5.56 Interleukin 12 receptor, beta 1
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were altered respectively. There were 277 unique genes at
4 h and 912 genes at 24 h with a RSV/control ratio of C2.0
or B0.5. Three previous microarray studies with a smaller
number of probe sets and genes have reported gene
expression profile associated with RSV infection in distal
airway epithelial cells (A549 cells) (Kong et al. 2003;
Martinez et al. 2007; Zhang et al. 2001). Our study char-
acterized gene expression pattern in proximal airway cells,
an early target of RSV. Compared to these previous studies,
our results showed some similarity and differences. All
studies showed significant induction of inflammation-rela-
ted genes, including many cytokines and chemokines, and
induction of genes involved in cell growth/proliferation,
cellular protein metabolism and cytoskeleton organization.
Some of the unique results from our study were early effects
on genes involved in neuroactive ligand-receptor interac-
tions and later effects on a repair enzyme, arginase II.
The neuroactive ligand-receptor interaction pathway
contains 11 highly significant genes with a RSV/control
ratio of C2.0 or B0.5 (Table 1). These genes included six
that encode G protein-related receptors (HCRTR1,
TACR1, AGTR2, NGFFR1, GRM5 and AVPR1A), three
that encode neurotransmission-related receptors (P2RX2,
GRID1 and GABRG2) and two that encode receptors with
Table 6 Genes in cytokine–cytokine receptor interaction pathway that were differentially expressed at 24 h (24 H) after RSV infection. Fold
changes at 4 h (4 H) are also shown
UniGene Symbol Fold Gene name
4 H 24 H
Hs.1349 CSF2 4.04 21.38 Colony stimulating factor 2 (granulocyte–macrophage)
Hs.415768 NGFR 1.51 12.34 Nerve growth factor receptor (TNFR superfamily, member 16)
Hs.411311 IL24 1.21 4.52 Interleukin 24
Hs.120658 OSMR 1.45 3.76 Oncostatin M receptor
Hs.376208 LTB 1.14 3.68 Lymphotoxin beta (TNF superfamily, member 3)
Hs.389874 TSLP 1.44 3.52 Thymic stromal lympho poietin
Hs.272373 IL20 1.09 3.26 Interleukin 20
Hs.624 IL8 1.11 3.06 Interleukin 8
Hs.173894 CSF1 2.69 2.88 Colony stimulating factor 1 (macrophage)
Hs.73793 VEGF 1.37 2.83 Vascular endothelial growth factor
Hs.583348 INHBA 1.36 2.81 Inhibin, beta A (activin A, activin AB alpha polypeptide)
Hs.169191 CCL23 1.36 2.55 Chemokine (c-c motif) ligand 23
Hs.507621 FLT1 -1.08 2.53 Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor
receptor)
Hs.2303 EPO 1.40 2.49 Erythropoietin
Hs.89679 IL2 4.05 2.44 Interleukin 2
Hs.1048 KITLG -1.19 2.29 KIT ligand
Hs.23581 LEPR 1.17 2.24 Leptin receptor
Hs.520414 IFNGR1 1.21 2.19 Interferon gamma receptor 1
Hs.75765 CXCL2 1.04 2.18 Chemokine (c-X-c motif) ligand 2
Hs.557403 IL1R1 -1.17 -2.27 Interleukin 1 receptor, type I
Hs.213467 TNFRSF10D -1.26 -2.27 Tumor necrosis factor receptor superfamily, member 10D, decoy with truncated death domain
Hs.181315 IFNAR1 1.01 -3.45 Interferon (alpha, beta and omega) receptor 1
Hs.105407 EDA -2.35 -5.00 Ectodysplasin A


























Fig. 1 Confirmation of expression of 7 upregulated genes by Q-PCR.
n = 4 for microarray; n = 4 experiments in bronchial epithelial cells
from 4 different donors for Q-PCR













































IL-8Fig. 2 Effects of RSV on the
release of CSF2 (GMCSF) and
interleukin-8 (IL-8). BEAS-2B
cells were incubated with 0.1,
0.3 and 1.0 moi of RSV for
48 h. * p \ 0.05 vs. no RSV.
n = 4–6 each
Upregulated Genes Downregulated Genes









Fig. 3 Venn diagrams
comparing probe sets
differentially expressed at 4 and
24 h post-infection. Numbers in
each area represent the numbers
of probe sets
Table 7 Top ten genes that were up- and down-regulated at both 4 and 24 h after RSV infection
UniGene Symbol Gene name
Upregulated genes
Hs.436360 ATP6V0D2 ATPase, H? transporting, lysosomal 38 kDa, V0 subunit d isoform 2
Hs.408336 OTOA Otoancorin
Hs.371727 SCNN1G Sodium channel, non-voltage-gated 1, gamma
Hs.469116 SLC9A1 Solute carrier family 9 (sodium/hydrogen exchanger), isoform 1 (antiporter, Na?/H?, amiloride sensitive)
Hs.529793 SMA5 SMA5
Hs.268554 CYP4F8 Cytochrome P450, family 4, subfamily F, polypeptide 8
Hs.269180 EPB41L4B Erythrocyte membrane protein band 4.1 like 4B
Hs.8739 ELP2 Signal transducer and activator of transcription 3 interacting protein 1
Hs.97432 PRKCE Protein kinase C, epsilon
Hs.162032 HBP1 HMG-box transcription factor 1
Downregulated genes
Hs.1183 DUSP2 Dual specificity phosphatase 2
Hs.303023 TUBB1 Tubulin, beta 1
Hs.567495 TRNT1 tRNA nucleotidyl transferase, CCA-adding, 1
Hs.520189 ELOVL5 ELOVL family member 5, elongation of long chain fatty acids
Hs.146050 PTPRG Protein tyrosine phosphatase, receptor type, G
Hs.531754 MAP2K7 Mitogen-activated protein kinase 7
Hs.120267 TSGA10 Testis specific, 10
Hs.66739 KRT12 Keratin 12 (Meesmann corneal dystrophy)
Hs.225936 SYN1 Synapsin I
Hs.134565 SIRPB1 Signal-regulatory protein beta 1
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endocrine and paracrine functions (GIPR and VIPR1). Two
genes (TACR1, VIPR1) are known to be related to RSV
infection. TACR1 belongs to a family of genes that func-
tion as receptors for tachykinin substance P (neurokinin 1).
RSV infection increases the mRNA expression of TACR1
(Auais et al. 2003; King et al. 2001; Piedimonte 2003).
Upregulation TACR1 would further enhance the substance
P-mediated signaling during RSV-induced airway inflam-
mation and dysfunction (Amadesi et al. 2001; Dakhama
et al. 2005; Joos et al. 1994; Tan et al. 2008; Tripp et al.
2000). Persistent RSV infection in mice decreases VIP
signaling (Tan et al. 2008). Downregulation of VIPR1 in
our study is consistent with this observation. None of the
other neuroactive ligand-receptor genes have been reported
previously to be associated with RSV infection. These









































Fig. 4 Expression of six genes that were significantly altered at both
4 and 24 h post-infection and were also biomarkers for respiratory




AMP-activated protein kinase family member 5NUAK12.54Hs.524692
Cytoplasmic linker 2CYLN22.28Hs.255664
Spondin 1, extracellular matrix proteinSPON13.92Hs.445818 
Muscleblind-like 2 (Drosophila)MBNL22.12Hs.125715
BTB and CNC homology 1, basic leucine zipper transcription factor 1BACH12.14Hs.154276
Inositol polyphosphate-5-phosphatase, 75 kDaINPP5B2.19Hs.449942 
Arginase, type IIARG22.06Hs.592312




Fig. 5 Hierarchical clustering
of the 912 differentially
expressed genes at 24 h after
RSV infection. a The heat map.
The arrow indicates the location
of the cluster that contains IL-8
and arginase II; b genes in this
cluster
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neuroactive ligand-receptor interaction that can be acti-
vated early after RSV infection. These characteristic pat-
terns underscore the unique localization of dendritic cells
within bronchial epithelium and their critical role in
respiratory viral infections (Grayson and Holtzman 2007).
Early changes in these receptor genes are consistent with
alterations in neuroimmune mechanisms that have been
linked to airway inflammation and airway hyper respon-
siveness following RSV infection (Krishnan et al. 2004;
Piedimonte 2003).
By 24 h after RSV infection, many more genes and
signaling pathways were altered (Table 2). Alterations in
some of these pathways were qualitatively similar to those
shown in previous microarray studies. The p53 signaling
pathway regulates cell growth and apoptosis induced by
genotoxic and non-genotoxic stresses. Twelve genes were
in the p53 pathway (Table 3), including upregulation of
MDM2, a critical negative regulator of p53, that may
contribute to the inhibition of p53 signaling and the anti-
apoptotic effects in lung epithelial cells (Bitko et al. 2007;
Groskreutz et al. 2007; Monick et al. 2005; Takeuchi et al.
1998; Thomas et al. 2002). Downregulation of pro-apop-
totic genes (e.g., FADD, CASP 8) and upregulation of
antiapoptotic genes (e.g., BIRC3, XIAP) may further
inhibit apoptosis during RSV infection (Table 4). The
JAK-STAT signaling pathway is another important path-
way known to be activated by RSV in response to type I
interferon’s (Kong et al. 2003) (Ramaswamy et al. 2004).
There were 17 genes in this pathway (Table 5). Another
DNA microarray study in A549 cells also identified genes
containing STAT-binding elements (Kong et al. 2003).
Activation of the JAK-STAT pathway also has been shown
in previous non-gene profiling studies (Nguyen et al. 1997;
Ramaswamy et al. 2004; Tarnawski and Jones 1998). The
cytokine-cytokine receptor interaction pathway contained
genes that are well known to be induced by RSV in lung
epithelial cells (Table 6) (Arnold et al. 1994) (Becker et al.
1991) (Casola et al. 2001) (Fiedler et al. 1995) (Pazdrak
et al. 2002) (Saito et al. 1997) (Soukup and Becker 2003)






























Fig. 6 Up-regulation of arginase II by RSV in primary human
bronchial epithelial cells. Human bronchial epithelial cells were
treated with RSV at multiplicity of infection (MOI) of 1.0 and 2.0.
Arginase II protein expression was measured at 48 h post-infection.
Upper panel shows a representive western blot. Lower panel is the
densitometry result. n = 3–4 independent experiments. * p \ 0.05
vs. time 0 or MOI = 0













































Control siRNA-AII RSV RSV+siRNA-AII
Control siRNA-AII RSV RSV+SiRNA-AII














Fig. 7 Effects of arginase II
knockdown on RSV-induced
injury in primary human
bronchial epithelial cells.
a Western blot analysis of
arginase II in cells with or
without arginase II siRNA
pretreatment. Knockdown of
arginase II gene expression with
siRNA increased the release of
IL-8; b LDH; c and histone;
d induced by RSV. n = 4
independent experiments.
* p \ 0.05 vs. control;
# p \ 0.05 vs. RSV
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2001). Genes in the cytokine–cytokine receptor interaction
pathways included three TNF/TNF receptor family genes
(LTB, NGFR, TNFRSF10D), two IFN-related genes (IF-
NAR1, IFNGR1), six interleukin family genes (IL12RB1,
IL1R1, IL2, IL20, IL24, IL8) and 4 cytokine/chemokine
genes (CCL23, CSF1, CSF2, CXCL2). We also noted
upregulation of VEGF and FLT1, a VEGF receptor gene.
Upregulation of these two genes may explain the activation
of VEGF signaling responsible for increased permeability
of bronchial epithelial cells during RSV infection (Kilani
et al. 2004; Lee et al. 2000).
We also matched the altered genes with respiratory
disease biomarkers in the Ingenuity Pathway Analysis.
Twenty-three and 92 genes were identified at 4 and 24 h
post-infection. Six genes were present at both time points.
Four genes (SCNN1G, EPB41L4B, CSF1, PTEN) were
upregulated, one gene (TUBB1) was down-regulated at 4
and 24 h and one gene (ESR2) was upregulated at 4 h, but
downregulated at 24 h post-infection. These six genes may
not only be pathogenetically important in RSV infection
(e.g., CSF2 and TUBB1) (Arnold et al. 1994; Huang et al.
2005; Noah and Becker 1993), but may also serve as bio-
markers of RSV infection.
The 92 respiratory disease biomarker genes also con-
tain arginase II gene (ARG2). Arginase II is the mito-
chondrial isoform of arginase that catalyzes the
conversion of L-arginine to L-ornithine and urea (Morris
2006). Arginase II is expressed constitutively in a number
of extra-hepatic tissues, including bronchial epithelial
cells (Que et al. 1998). Hierarchical clustering linked
ARG2 closely to IL8, a major RSV-induced chemokine
gene. The same cluster also contains other cytokine genes
that are important in inflammation, including IL-24 (4.52-
fold) and CXCL2 (2.18-fold). Upregulation of ARG2
during RSV infection is important in limiting cell injury
since knockdown of arginase II gene expression by siR-
NA increased the release of IL-8, histone and LDH
induced by RSV. This is consistent with the putative role
of arginase II in tissue repair (Morris 2005). The potential
implication of upregulation of arginase II during RSV
infection may also extend to the pathogenesis of human
asthma. Increased arginase expression and activity has
been linked to the pathogenesis of asthma (King et al.
2004) (Vercelli 2003) (Zimmermann and Rothenberg
2006). Using gene expression profiling, Zimmerman et al.
found genes related to metabolism of arginine, including
cationic amino acid transporter 2, arginase I and arginase
II, prominently expressed in an experimental model of
asthma (Zimmermann et al. 2003). Since RSV is an
important exacerbating factor and trigger for asthma
(Kalina and Gershwin 2004; Openshaw 2003; Stein et al.
1999), arginase II may be one of the important mecha-
nistic links between RSV infection and asthma.
In conclusion, using DNA microarray, we provided the
gene expression profile in human bronchial epithelial cells
during RSV infection. The gene expression profile in
proximal airway cells share some similarity with those
shown in distal lung cells, primarily in inflammation and
cell growth and cell death. Our results also reveal novel
genes and pathways that may be important in the patho-
genesis of RSV infection and the associated complications.
More significantly, we identified a set of genes that may be
used as biomarkers of RSV infection. Since these genes are
expressed in proximal airway cells, the clinical utility of
these biomarker genes can be readily tested in the sputum
samples in the future.
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